November 12, 2021
Targeted STAT3 Degradation Leads to Remodeling of an Immunosuppressive Tumor Microenvironment and Subsequent Sensitization to Immune Checkpoint Inhibition
SITC 2021
Liquid Tumors
Solid Tumors
Read More
October 28, 2021
Considerations for E3 Ligase Pairing and Screening of Immune-Inflammation Targets
4th Annual TPD Summit
Read More
October 27, 2021
Safety, PK and PD from Single Ascending Does Portion of KT-474 Phase 1 Trial in Healthy Volunteers
4th Annual TPD Summit
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
October 27, 2021
Understanding PK/PD for Development of STAT3 Degraders in Oncology Indications
4th Annual TPD Summit
Liquid Tumors
Solid Tumors
Read More
October 26, 2021
TPD Workshop: De-risking Clinical Development of a Novel Protein Degrader
4th Annual TPD Summit
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
September 21, 2021
Identification of Highly Potent and Selective Interleukin-1 Receptor Associates Kinase 4 (IRAK4) Degrader for the Treatment of Autoimmune Disease
European Protein Degradation Congress
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
September 15, 2021
Inventing New Medicines with Targeted Protein Degradation
Undruggable Leaders Forum
Read More
July 12, 2021
Targeting STAT3 with Selective Protein Degraders for the Treatment of PTCL
13th Annual T-Cell Lymphoma Forum
PTCL
Read More
June 20, 2021
KT-413, a Novel IRAKIMiD Degrader of IRAK4 and IMiD Substrates, has a Differentiated MOA that Leads to Single-agent and Combination Regressions in MYD88MT Lymphoma Models
16th Annual International Conference on Malignant Lymphoma (ICML) Virtual Meeting
MYD88 Tumors
Read More
May 26, 2021
Drugging Tissue-Restricted E3 Ligases
Ligase Targeting Drug Development Summit
Read More